logo
UNICEF Reaching Children Caught In Sudan's Perfect Storm

UNICEF Reaching Children Caught In Sudan's Perfect Storm

Forbes15-04-2025

On March 2, 2025, children walk back home from a UNICEF-supported child-friendly space in Al Houri internally displaced people's (IDP) camp in Gedaref State, Sudan. At the camp, UNICEF and partners are delivering an integrated emergency response in water, sanitation and hygiene, health and nutrition, child protection and education, benefiting children and their families from displaced and host communities.
As the brutal armed conflict in Sudan moves into its third year, the country is mired in the world's largest humanitarian and child displacement polycrisis.
Life is a daily battle to survive for 30 million people in need of humanitarian assistance. Nearly 15 million people have been displaced inside Sudan and across borders; more than half of those displaced are children. Almost one in three are under the age of 5.
Famine is spreading, vaccination rates are dropping. Sexual violence against children is being used as a weapon of war. About 90 percent of children are out of school.
In areas where opportunities to return arise, unexploded ordnance and limited access to essential services put children's lives at heightened risk.
On April 5, 2025, mothers and children gathered at Saudi Hospital in Omdurman, Khartoum State, Sudan, to access essential health services. The hospital receives lifesaving vaccines, nutrition supplies and essential medicines from UNICEF.
The day the war began — April 15, 2023 — Fatuma, 13, was taking a test at her school in Khartoum. "In the middle of the exam, a teacher entered and asked us to put the papers away," Fatuma said. "She didn't tell us why. She told us to go straight home and not to look around or linger in the streets."
By the time she arrived home, her family was in a state of panic. As the sound of intense fighting grew nearer, the family fled in search of safety. Since then, they have moved six times. Home for now is a camp for the internally displaced in Kassala.
UNICEF has been on the ground in Sudan since the 1950s, working to improve critical services and provide support and protection for vulnerable children. In 2024, UNICEF and partners provided psychosocial counseling, education and protection services to 2.7 million children and caregivers, reached over 9.8 million children and families with safe drinking water, screened 6.7 million children for malnutrition and provided lifesaving treatment for 422,000 of them.
UNICEF continues to prioritize lifesaving interventions in conflict zones and also supports displaced populations and host communities in safer areas, providing essential services and support.
UNICEF Representative to Sudan, Sheldon Yett, center in UNICEF vest, enjoys a light moment with children at Ammar Ibn Yasir School for Boys on April 5, 2025. The school hosts a safe learning space for internally displaced children in Karrari, Khartoum State. Safe learning spaces are places where children can meet, play, sing, have fun together and access learning activities supported by teachers.
But access by humanitarian actors to children is deteriorating due to the intensity of the conflict and to restrictions or bureaucratic impediments imposed by government authorities or other armed groups.
In 2024, over 60 percent of UNICEF's aid deliveries were delayed amid a highly volatile security environment. Although no missions were cancelled or aborted, these repeated delays disrupted the timely delivery of assistance and hindered access to children in urgent need.
In Central Darfur, Sudan, UNICEF partners and volunteers transport cartons of ready-to-use therapeutic food by raft in September 2024, following the collapse of the Wadi Mornei bridge due to flooding.
Last week, dozens of civilians, including at least 23 children, and several aid workers were reportedly killed in attacks in Al Fasher and Abu Shouk and Zamzam IDP camps. Over the past three months, more than 140 children have been killed or maimed in Al Fasher alone, underscoring the relentless toll of the ongoing war on children in Sudan and the extreme conditions facing humanitarian workers.
"Two years of violence and displacement have shattered the lives of millions of children across Sudan," said UNICEF Executive Director Catherine Russell. "Needs continue to outpace humanitarian funding. With the rainy season around the corner, children who are already reeling from malnutrition and disease will be harder to reach. I urge the international community to seize this pivotal window for action and step up for Sudan's children.'
"We have the expertise and the resolve to scale up our support, but we need access and sustained funding," Russell continued. "Most of all, children in Sudan need this horrific conflict to end.'
On April 5, 2025, a child shows his drawing of a tank at a UNICEF-supported child-friendly space (CFS) in the Alhatana neighborhood, Omdurman, Khartoum State, Sudan.
Right now, the lives of the most vulnerable children hang in the balance as conflicts and crises jeopardize the care and protection that they deserve. Dependable, uninterrupted and effective foreign aid is critical to the well-being of millions of children. Please contact your members of Congress and urge them to support ongoing U.S. investments in foreign assistance.
Help UNICEF reach more children with urgently needed support. Please donate today.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Dozens of Palestinians killed making their way to Gaza aid hub: Report
Dozens of Palestinians killed making their way to Gaza aid hub: Report

Yahoo

time16 hours ago

  • Yahoo

Dozens of Palestinians killed making their way to Gaza aid hub: Report

Dozens of Palestinians were killed Sunday when going to a Gaza aid hub, officials and witnesses said, according to The Associated Press. Crowds were fired upon by Israeli forces close to 1,000 yards from an Israeli-supported aid foundation's site, witnesses said, the AP reported. Thirty-one people died and 170 were injured, the Gaza Health Ministry said, according to the outlet. Israel's army said in a statement it was 'currently unaware of injuries caused by (Israeli military) fire within the Humanitarian Aid distribution site,' according to the AP. A statement from the Gaza Humanitarian Foundation pushed back on stories of disorder and gunfire near its sites and said that aid was provided by the foundation 'without incident,' the outlet reported. Israeli military action in the Gaza Strip since the deadly Oct. 7, 2023, attack on the country has caused the mass destruction of infrastructure in the territory, as well as widespread death and injury among the residents of Gaza. The dire situation faced by Gaza's residents has resulted in international pressure on Israel over its treatment of those living in the territory, with figures like the newly-minted Pope Leo XIV calling for a ceasefire in the Gaza Strip and British Prime Minister Keir Starmer, Canadian Prime Minister Mark Carney and French President Emmanuel Macron saying in a recent statement that they were 'strongly' against 'the expansion of Israel's military operations in Gaza.' 'The level of human suffering in Gaza is intolerable. Yesterday's announcement that Israel will allow a basic quantity of food into Gaza is wholly inadequate. We call on the Israeli Government to stop its military operations in Gaza and immediately allow humanitarian aid to enter Gaza,' the joint statement, posted on the social platform X by Carney on May 19, read. The Associated Press contributed to this report. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

Parker Institute Showcases Breakthroughs in Immunotherapy at ASCO 2025 as CEO Dr. Karen Knudsen Receives Prestigious Honor
Parker Institute Showcases Breakthroughs in Immunotherapy at ASCO 2025 as CEO Dr. Karen Knudsen Receives Prestigious Honor

Yahoo

time3 days ago

  • Yahoo

Parker Institute Showcases Breakthroughs in Immunotherapy at ASCO 2025 as CEO Dr. Karen Knudsen Receives Prestigious Honor

Glioblastoma survival extends to 14.6 months; dual-target CAR T shrinks tumors in 85% of patients—milestone results among 50+ presentations across the PICI Network CHICAGO, May 29, 2025--(BUSINESS WIRE)--As the global oncology community gathers for the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting (May 30–June 3), the Parker Institute for Cancer Immunotherapy (PICI) is demonstrating how bold science, accelerated through collaborative networks, can drive meaningful progress where patients need it most. At a pivotal moment when scientific breakthroughs in immunotherapy are arriving alongside heightened pressure for faster, smarter impact, PICI's integrated model shows how to compress timelines from discovery to patient care. PICI's presence spans more than 50 presentations including 16 oral sessions, 30+ poster sessions, 10 e-papers and a featured clinical science symposium. This volume reflects not only the strength of the PICI network but also a unique ability to support promising work early and help carry it across the finish line, from foundational discoveries to practice-changing trials. Glioblastoma Breakthroughs: New Hope for Cancer's Most Formidable Challenge After decades of limited progress in glioblastoma, where median survival has hovered around one year, multiple PICI-supported teams are reporting clinical responses that suggest the field may be turning a corner. These advances demonstrate how collaboration, persistence and innovation can converge on even the most intractable problems: Stanford Medicine researchers achieved median overall survival of 14.6 months in recurrent glioblastoma patients using B7H3 CAR T cells delivered directly to the brain via dual Ommaya reservoirs. The Phase 1 study established a recommended Phase 2 dose and demonstrated manageable inflammation using IL-1 blockade, offering a tangible advance in a cancer where meaningful clinical progress has long remained elusive. (Crystal Mackall, MD, Director of the PICI Center at Stanford; Michelle Monje, MD, PhD — Abstract #2018) University of Pennsylvania investigators reported tumor shrinkage in 85% of evaluable patients using bivalent CAR T-cell therapy targeting EGFR and IL13Rα2 in recurrent glioblastoma. Delivered into the cerebroventricular space without lymphodepletion, the engineered T cells persisted in cerebrospinal fluid and blood for up to one year, marking an encouraging step toward sustained response and long-term disease management. (Carl June, MD, Director of the PICI Center at Penn; Donald O'Rourke, MD — Abstract #102) UCSF and Memorial Sloan Kettering researchers identified more than 700 glioma-specific, splice-derived neoantigens using the SNIPP antigen discovery platform. These targets elicited CD8+ T-cell responses in vitro and many were conserved across tumors, opening the door to scalable, potentially off-the-shelf TCR-based therapies. (Hideho Okada, MD, PhD, UCSF — Abstract #2519) Leadership Recognition: PICI CEO Receives ASCO's Highest Honor Dr. Karen Knudsen, PICI's CEO, will receive the Allen S. Lichter Visionary Leader Award during ASCO's opening session, recognizing a career spent building bridges from bench to patient and helping reshape how academic institutions, nonprofits and companies move from insight to implementation. Saturday, May 31, 9:45 AM–12:00 PM CDT, Room N - Hall B1 Dr. Knudsen will also join Endpoints News for a live discussion on research acceleration, regulatory pace and how PICI's model aligns research, policy and investment with the realities facing patients today. Wednesday, June 4, 10:35 AM CDT, Endpoints Stage Network-Wide Impact: Where Discovery Meets Delivery PICI-supported science appears across the ASCO agenda, tackling critical questions in high-burden cancers through studies connected by a framework that enables speed, coordination and clinical relevance. These presentations reflect a hallmark of the PICI approach: compressing the distance between new insight and patient impact, often turning early-stage ideas into clinical action within just a few years. Melanoma Advances DREAMseq Final Results: Optimal treatment sequencing in BRAF-mutant metastatic melanoma (Jedd Wolchok, MD, PhD, Weill Cornell; Antoni Ribas, MD, PhD, UCLA — Abstract #9506) Quadruple Immunotherapy: IL-6 blockade combined with checkpoint inhibitors in advanced melanoma (F. Stephen Hodi, MD, Dana-Farber — Abstract #9510) Neoadjuvant Strategy: Pembrolizumab in clinical stage IIB/C melanoma (Alexander Huang, MD, University of Pennsylvania — Abstract #9502) Prostate Cancer Innovation COMRADE Trial: Olaparib plus radium-223 in castration-resistant prostate cancer with bone metastases (Eliezer Van Allen, MD, Dana-Farber — Abstract #5007) C3NIRA Trial: Triplet chemo-immunotherapy induction followed by PARP inhibitor maintenance (Padmanee Sharma, MD, PhD, MD Anderson — Abstract #5008) Breast and Lung Cancer Precision Strategies NeoSTAR Trial: Response-guided neoadjuvant sacituzumab govitecan plus pembrolizumab in early triple-negative breast cancer (Elizabeth Mittendorf, MD, PhD, Dana-Farber — Abstract #511) ADRIATIC Correlatives: Genomic analysis of long-term responders in limited-stage small cell lung cancer (David Barbie, MD, Dana-Farber — Abstract #8014) Translational Platforms INCIPIENT Trial: CARv3-TEAM-E immunological correlates in recurrent glioblastoma (Marcela Maus, MD, PhD, Massachusetts General Hospital — Abstract #2008) BRCA1/2 DNA Vaccines: Plasmid-based immunotherapy platform with and without IL-12 (Robert Vonderheide, MD, DPhil, University of Pennsylvania — Abstract #10505) About the Parker Institute for Cancer Immunotherapy The Parker Institute for Cancer Immunotherapy (PICI) accelerates breakthrough immune therapies from discovery to patient impact through a collaborative network of the nation's top cancer centers. Founded in 2016 through the vision of Sean Parker, PICI unites leading institutions in a translational engine built for speed, coordination and clinical relevance. Unlike traditional research models, PICI goes beyond discovery by actively advancing promising innovations through clinical testing, company formation, incubation and commercialization. PICI supports high-risk, high-reward science with shared goals, data and infrastructure, helping compress timelines from laboratory discovery to patient access. The institute has supported more than 1,000 investigators across its network and created a portfolio of 17 biotech ventures with over $4 billion in raised capital. By integrating scientific excellence with entrepreneurial execution, PICI is reimagining how cures are made and accelerating their path to the people who need them most. Learn more at Follow #PICIatASCO for updates throughout the meeting. View source version on Contacts Media Contact: Eric McKeebyHead of Communications & MarketingParker Institute for Cancer Immunotherapy(646) 522-4605emckeeby@

Parker Institute Showcases Breakthroughs in Immunotherapy at ASCO 2025 as CEO Dr. Karen Knudsen Receives Prestigious Honor
Parker Institute Showcases Breakthroughs in Immunotherapy at ASCO 2025 as CEO Dr. Karen Knudsen Receives Prestigious Honor

Business Wire

time3 days ago

  • Business Wire

Parker Institute Showcases Breakthroughs in Immunotherapy at ASCO 2025 as CEO Dr. Karen Knudsen Receives Prestigious Honor

CHICAGO--(BUSINESS WIRE)--As the global oncology community gathers for the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting (May 30–June 3), the Parker Institute for Cancer Immunotherapy (PICI) is demonstrating how bold science, accelerated through collaborative networks, can drive meaningful progress where patients need it most. At a pivotal moment when scientific breakthroughs in immunotherapy are arriving alongside heightened pressure for faster, smarter impact, PICI's integrated model shows how to compress timelines from discovery to patient care. PICI's presence spans more than 50 presentations including 16 oral sessions, 30+ poster sessions, 10 e-papers and a featured clinical science symposium. This volume reflects not only the strength of the PICI network but also a unique ability to support promising work early and help carry it across the finish line, from foundational discoveries to practice-changing trials. Glioblastoma Breakthroughs: New Hope for Cancer's Most Formidable Challenge After decades of limited progress in glioblastoma, where median survival has hovered around one year, multiple PICI-supported teams are reporting clinical responses that suggest the field may be turning a corner. These advances demonstrate how collaboration, persistence and innovation can converge on even the most intractable problems: Stanford Medicine researchers achieved median overall survival of 14.6 months in recurrent glioblastoma patients using B7H3 CAR T cells delivered directly to the brain via dual Ommaya reservoirs. The Phase 1 study established a recommended Phase 2 dose and demonstrated manageable inflammation using IL-1 blockade, offering a tangible advance in a cancer where meaningful clinical progress has long remained elusive. (Crystal Mackall, MD, Director of the PICI Center at Stanford; Michelle Monje, MD, PhD — Abstract #2018) University of Pennsylvania investigators reported tumor shrinkage in 85% of evaluable patients using bivalent CAR T-cell therapy targeting EGFR and IL13Rα2 in recurrent glioblastoma. Delivered into the cerebroventricular space without lymphodepletion, the engineered T cells persisted in cerebrospinal fluid and blood for up to one year, marking an encouraging step toward sustained response and long-term disease management. (Carl June, MD, Director of the PICI Center at Penn; Donald O'Rourke, MD — Abstract #102) UCSF and Memorial Sloan Kettering researchers identified more than 700 glioma-specific, splice-derived neoantigens using the SNIPP antigen discovery platform. These targets elicited CD8+ T-cell responses in vitro and many were conserved across tumors, opening the door to scalable, potentially off-the-shelf TCR-based therapies. (Hideho Okada, MD, PhD, UCSF — Abstract #2519) Leadership Recognition: PICI CEO Receives ASCO's Highest Honor Dr. Karen Knudsen, PICI's CEO, will receive the Allen S. Lichter Visionary Leader Award during ASCO's opening session, recognizing a career spent building bridges from bench to patient and helping reshape how academic institutions, nonprofits and companies move from insight to implementation. Saturday, May 31, 9:45 AM–12:00 PM CDT, Room N - Hall B1 Dr. Knudsen will also join Endpoints News for a live discussion on research acceleration, regulatory pace and how PICI's model aligns research, policy and investment with the realities facing patients today. Wednesday, June 4, 10:35 AM CDT, Endpoints Stage Network-Wide Impact: Where Discovery Meets Delivery PICI-supported science appears across the ASCO agenda, tackling critical questions in high-burden cancers through studies connected by a framework that enables speed, coordination and clinical relevance. These presentations reflect a hallmark of the PICI approach: compressing the distance between new insight and patient impact, often turning early-stage ideas into clinical action within just a few years. Melanoma Advances DREAMseq Final Results: Optimal treatment sequencing in BRAF-mutant metastatic melanoma (Jedd Wolchok, MD, PhD, Weill Cornell; Antoni Ribas, MD, PhD, UCLA — Abstract #9506) Quadruple Immunotherapy: IL-6 blockade combined with checkpoint inhibitors in advanced melanoma (F. Stephen Hodi, MD, Dana-Farber — Abstract #9510) Neoadjuvant Strategy: Pembrolizumab in clinical stage IIB/C melanoma (Alexander Huang, MD, University of Pennsylvania — Abstract #9502) Prostate Cancer Innovation COMRADE Trial: Olaparib plus radium-223 in castration-resistant prostate cancer with bone metastases (Eliezer Van Allen, MD, Dana-Farber — Abstract #5007) C3NIRA Trial: Triplet chemo-immunotherapy induction followed by PARP inhibitor maintenance (Padmanee Sharma, MD, PhD, MD Anderson — Abstract #5008) Breast and Lung Cancer Precision Strategies NeoSTAR Trial: Response-guided neoadjuvant sacituzumab govitecan plus pembrolizumab in early triple-negative breast cancer (Elizabeth Mittendorf, MD, PhD, Dana-Farber — Abstract #511) ADRIATIC Correlatives: Genomic analysis of long-term responders in limited-stage small cell lung cancer (David Barbie, MD, Dana-Farber — Abstract #8014) Translational Platforms INCIPIENT Trial: CARv3-TEAM-E immunological correlates in recurrent glioblastoma (Marcela Maus, MD, PhD, Massachusetts General Hospital — Abstract #2008) BRCA1/2 DNA Vaccines: Plasmid-based immunotherapy platform with and without IL-12 (Robert Vonderheide, MD, DPhil, University of Pennsylvania — Abstract #10505) About the Parker Institute for Cancer Immunotherapy The Parker Institute for Cancer Immunotherapy (PICI) accelerates breakthrough immune therapies from discovery to patient impact through a collaborative network of the nation's top cancer centers. Founded in 2016 through the vision of Sean Parker, PICI unites leading institutions in a translational engine built for speed, coordination and clinical relevance. Unlike traditional research models, PICI goes beyond discovery by actively advancing promising innovations through clinical testing, company formation, incubation and commercialization. PICI supports high-risk, high-reward science with shared goals, data and infrastructure, helping compress timelines from laboratory discovery to patient access. The institute has supported more than 1,000 investigators across its network and created a portfolio of 17 biotech ventures with over $4 billion in raised capital. By integrating scientific excellence with entrepreneurial execution, PICI is reimagining how cures are made and accelerating their path to the people who need them most. Learn more at Follow #PICIatASCO for updates throughout the meeting.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store